Phase II Study of Estramustine and Vinorelbine in Hormone-Refractory Prostate Carcinoma Patients

Klein LA, 1968, N Engl J Med, 300, 26

10.1002/1097-0142(19930201)71:3+<1098::AID-CNCR2820711432>3.0.CO;2-G

Stears Me, 1988, J Cell Biol, 107, 2647, 10.1083/jcb.107.6.2647

Cannobio L, 1989, Semin Oncol, 16, 33

Coltman CA, 1994, A new agent for the treatment of non-small cell lung cancer. A summary. Semin Oncol, 21, 1

Donehower RC, 1993, Anticancer drugs derived from plants, 409

Seidman AD, 1992, Curley T. Estramustine and vinblastine: use of prostate specific antigen as a clinical trial end point for hormone refractory prostatic cancer. J Urol, 147, 931

Speicher LA, 1992, Combined antimicrotubule activity or estramustine and taxol in human prostatic car-cinoma cell lines. Cancer Res, 52, 4433

Hudes GR, 1997, J Clin Oncol, 15, 3156, 10.1200/JCO.1997.15.9.3156

Pienta KJ, 1994, J Clin Oncol, 12, 2005, 10.1200/JCO.1994.12.10.2005

10.1080/01621459.1958.10501452

Dawson NA, 1995, Antitumor activity of suramin in hormone-refractory prostate cancer controlling for hydrocortisone treatment and flutamide withdrawal as poten-tially confounding variables. Cancer, 76, 453

Sella A, 1994, J Clin Oncol, 12, 683, 10.1200/JCO.1994.12.4.683

De Kernion JN, 1988, Comparison of flutamide and Emcyt in hormone-refractory metastatic prostate cancer. Urology, 149, 1622

Tew KD, 1987, Urol Res, 15, 155

Rutberg M, 1989, Prostate, 15, 287, 10.1002/pros.2990150402

Attivissimo LA, 1996, Symptomatic improve-ment associated with combined estramustine and vinblastine chemotherapy for metastatic prostate cancer. Am J Clin Oncol, 19, 581